NCT04726722

Brief Summary

To evaluate a nine-week adaptable and person-centred I-CBT program that can be directed towards stress, anxiety and depressive symptoms in persons with CVD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
215

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 22, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 27, 2021

Completed
2.1 years until next milestone

Study Start

First participant enrolled

March 13, 2023

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

November 24, 2025

Status Verified

November 1, 2025

Enrollment Period

2.3 years

First QC Date

January 22, 2021

Last Update Submit

November 18, 2025

Conditions

Keywords

Cardiovascular diseasePsychological distressInternet-based cognitive behavioural therapy

Outcome Measures

Primary Outcomes (3)

  • Change in stress from baseline to 9 weeks on the 10 item Perceived Stress Scale

    The 10-item Perceived Stress Scale is a valideted self-report of Stress. The instreument measures the degree to which individuals perceives their life situations as stressful. The 10 items are rated on a 5 point scale and higher scores means more stress

    From baseline to 9 weeks at the end of the intervention.

  • Change in anxiety from baseline to 9 weeks on the 7-item Generalized Anxiety Disorder Scale.

    General Anxiety Disorder scale is validagted self-resport that measure symptoms of general anxiety during the last two weeks. The 7-items range from 0 (not bothered at all) to 3 (nearly every day). A higher score indicate more anxiety and the cut-off 5 suggests at least mild anxiety.

    From baseline to 9 weeks at the end of the intervention.

  • Change in depressive symptoms from baseline to 9 weeks on the 9 item Patient Health Questionnaire.

    The 9-item Patient Health Questionnaire is a validated self-report that measure depressive symtpoms during the last two weeks. Each item is answered on a four graded scale where 0 means that the person not is affected and 3 where the person is affected several Days to almost every day. Higher numbers represents higher levels of depressive symptoms. A cut-off \>5 represents at least mild depression.

    From baseline to 9 weeks at the end of the intervention.

Study Arms (2)

Design of the CBT treatment content

EXPERIMENTAL

Patient determined CBT content (i.e. person-centered) vs. therapist determined I-CBT content

Behavioral: internet-based cognitive behavioral theraphy

Control of support and feedback

EXPERIMENTAL

Patient-controlled support and feedback (person-centred) vs. therapist -controlled.

Behavioral: internet-based cognitive behavioral theraphy

Interventions

When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules. Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired

Control of support and feedbackDesign of the CBT treatment content

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age 18 years and above
  • treatment for cardiovascular disease (CVD) according to European Society of Cardiology guidelines
  • stable CVD (New York Heart Association class I-III) and not having been hospitalised for CVD in in the last four weeks.
  • stress (Perceived Stress Scale (PSS)-10\>13 points) and/or
  • anxiety (i.e. General Anxiety Disorder Scale (GAD) ≥5 points) and/or
  • depressive symptoms (Patient Health Questionnaire-9 28 (PHQ-9) \> 5 points)

You may not qualify if:

  • severe CVD (New York Heart Association classification IV) or another severe chronic life-threatening disease
  • severe stress, anxiety or depression assessed as requiring acute treatment
  • not being able to dedicate 3-4 hours per week to participate in the program

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peter Johansson

Norrköping, Linköpings Universitet, 601 74, Sweden

Location

MeSH Terms

Conditions

Cardiovascular Diseases

Study Officials

  • Peter Johansson, Ph.D

    Department of Health, Medicine and Caring Sciences, Linkoping University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
FACTORIAL
Model Details: 2 x 2
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 22, 2021

First Posted

January 27, 2021

Study Start

March 13, 2023

Primary Completion

June 30, 2025

Study Completion

June 30, 2025

Last Updated

November 24, 2025

Record last verified: 2025-11

Locations